← FDA DRUG APPROVALS

FDA NDA · NDA218010

IDOSE TR

travoprost intracameral

Sponsor: GLAUKOS

APPLICATION
NDA218010
TYPE
NDA
ORIGINAL APPROVAL
2023-12-13
LATEST ACTION
2026-01-27
ROUTE
INTRACAMERAL
DOSAGE FORM
IMPLANT
MARKETING STATUS
Prescription

Products

IDOSE TR · ReferencePrescription
TRAVOPROST 75MCG · IMPLANT · INTRACAMERAL

Approval history

2026-01-27Labeling · Supplement 6 · standard — Letter ↗AP
2026-01-27Efficacy · Supplement 4 · standard — Letter ↗AP
2023-12-13Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →